Immunology of COVID-19: Current State of the Science

Adams, 2020, Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays, medRxiv Agostini, 2018, Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease, MBio, 9, e00221, 10.1128/mBio.00221-18 Ahmed, 2020, Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies, Viruses, 12, 254, 10.3390/v12030254 Ahn, 2018, Role of PD-1 during effector CD8 T cell differentiation, Proc. Natl. Acad. Sci. USA, 115, 4749, 10.1073/pnas.1718217115 Ahn, 2020, Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea, J. Korean Med. Sci., 35, e149, 10.3346/jkms.2020.35.e149 Alharbi, 2017, ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice, Vaccine, 35, 3780, 10.1016/j.vaccine.2017.05.032 Amanat, 2020, SARS-CoV-2 Vaccines: Status Report, Immunity, 52, 583, 10.1016/j.immuni.2020.03.007 Amanat, 2020, A serological assay to detect SARS-CoV-2 seroconversion in humans, Nat. Med., 10.1038/s41591-020-0913-5 André, 2003, Vaccinology: Past Achievements, Present Roadblocks and Future Promises, Vaccine, 21, 593, 10.1016/S0264-410X(02)00702-8 Andreakos, 2017, Interferon-λs: Front-Line Guardians of Immunity and Homeostasis in the Respiratory Tract, Front. Immunol., 8, 1232, 10.3389/fimmu.2017.01232 Antrobus, 2014, Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens, Mol. Ther., 22, 668, 10.1038/mt.2013.284 Arabi, 2016, Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians, BMC Anesthesiol., 16, 36, 10.1186/s12871-016-0198-x Arabi, 2020, Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study, Clin. Infect. Dis., 70, 1837, 10.1093/cid/ciz544 Asselta, 2020, ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy, medRxiv Bacher, 2016, Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans, Cell, 167, 1067, 10.1016/j.cell.2016.09.050 Bao, 2020, The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice, Nature, 10.1038/s41586-020-2312-y Bao, 2020, Reinfection could not occur in SARS-CoV-2 infected rhesus macaques, bioRxiv Barnes, 2020, Targeting potential drivers of COVID-19: Neutrophil extracellular traps, J. Exp. Med., 217, e20200652, 10.1084/jem.20200652 Baruah, 2020, Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV, J. Med. Virol., 92, 495, 10.1002/jmv.25698 Belhadi, 2020, A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19, medRxiv Bhattacharya, 2020, ). Development of Epitope-Based Peptide Vaccine Against Novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics Approach, J. Med. Virol., 10.1002/jmv.25736 Blanco-Melo, 2020, Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19, Cell, 10.1016/j.cell.2020.04.026 Borba, 2020, Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, JAMA Netw. Open, 3, e208857, 10.1001/jamanetworkopen.2020.8857 Bouvet, 2010, In vitro reconstitution of SARS-coronavirus mRNA cap methylation, PLoS Pathog., 6, e1000863, 10.1371/journal.ppat.1000863 Braud, 1998, HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C, Nature, 391, 795, 10.1038/35869 Braun, 2020, Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors, medRxiv Brooks, 1997, NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor, J. Exp. Med., 185, 795, 10.1084/jem.185.4.795 Bukreyeva, 2020, The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro, bioRxiv Cai, 2020, A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona virus Disease 2019, J. Infect. Dis., 10.1093/infdis/jiaa243 Callow, 1990, The time course of the immune response to experimental coronavirus infection of man, Epidemiol. Infect., 105, 435, 10.1017/S0950268800048019 Cameron, 2007, Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome, J. Virol., 81, 8692, 10.1128/JVI.00527-07 Cameron, 2012, Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model, PLoS ONE, 7, e45842, 10.1371/journal.pone.0045842 Camp, 2017, A Role for Neutrophils in Viral Respiratory Disease, Front. Immunol., 8, 550, 10.3389/fimmu.2017.00550 Campbell, 2020, Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles, bioRxiv Canton, 2018, MERS-CoV 4b protein interferes with the NF-κB-dependent innate immune response during infection, PLoS Pathog., 14, e1006838, 10.1371/journal.ppat.1006838 Cao, 2020, COVID-19: immunopathology and its implications for therapy, Nat. Rev. Immunol., 20, 269, 10.1038/s41577-020-0308-3 Cao, 2007, Disappearance of antibodies to SARS-associated coronavirus after recovery, N. Engl. J. Med., 357, 1162, 10.1056/NEJMc070348 Cao, 2010, Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients, Virol. J., 7, 299, 10.1186/1743-422X-7-299 Cao, 2020, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N. Engl. J. Med., 10.1056/NEJMoa2001282 Cao, 2020, High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019, Open Forum Infect. Dis., 7, a102, 10.1093/ofid/ofaa102 Cao, 2020, Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discov., 6, 11, 10.1038/s41421-020-0147-1 Carlin, 2018, Natural Killer Cell Recruitment to the Lung During Influenza A Virus Infection Is Dependent on CXCR3, CCR5, and Virus Exposure Dose, Front. Immunol., 9, 781, 10.3389/fimmu.2018.00781 Cervantes-Barragan, 2007, Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon, Blood, 109, 1131, 10.1182/blood-2006-05-023770 Cerwenka, 2001, Natural killer cells, viruses and cancer, Nat. Rev. Immunol., 1, 41, 10.1038/35095564 Chan, 2007, Association of ICAM3 genetic variant with severe acute respiratory syndrome, J. Infect. Dis., 196, 271, 10.1086/518892 Chang, 2011, Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity, Nat. Immunol., 12, 631, 10.1038/ni.2045 Channappanavar, 2016, Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice, Cell Host Microbe, 19, 181, 10.1016/j.chom.2016.01.007 Channappanavar, 2019, IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes, J. Clin. Invest., 130, 3625, 10.1172/JCI126363 Charbonneau, 2020, Developing a new class of engineered live bacterial therapeutics to treat human diseases, Nat. Commun., 11, 1738, 10.1038/s41467-020-15508-1 Chen, 2009, Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase, Proc. Natl. Acad. Sci. USA, 106, 3484, 10.1073/pnas.0808790106 Chen, 2019, Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome, Front. Microbiol., 10, 50, 10.3389/fmicb.2019.00050 Chen, 2020, Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor, Cell. Mol. Immunol., 10.1038/s41423-020-0426-7 Chen, 2020, Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, medRxiv Chen, 2020, Clinical and immunological features of severe and moderate coronavirus disease 2019, J. Clin. Invest., 10.1172/JCI137244 Chen, 2020, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J. Zhejiang Univ., 49 Chen, 2020, [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia], Zhonghua Jie He He Hu Xi Za Zhi, 43, 203 Chen, 2020, Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients, medRxiv Chen, 2020, Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients, Clin. Infect. Dis. Chen, 2020, The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes, medRxiv Chen, 2020, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv Cheng, 2005, ABO blood group and susceptibility to severe acute respiratory syndrome, JAMA, 293, 1450 Cheng, 2005, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur. J. Clin. Microbiol. Infect. Dis., 24, 44, 10.1007/s10096-004-1271-9 Cheung, 2005, Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis, J. Virol., 79, 7819, 10.1128/JVI.79.12.7819-7826.2005 Chien, 2006, Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome, Respirology, 11, 715, 10.1111/j.1440-1843.2006.00942.x Chu, 2004, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, 59, 252, 10.1136/thorax.2003.012658 Chu, 2016, Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways, J. Infect. Dis., 213, 904, 10.1093/infdis/jiv380 Chu, 2020, Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19, Clin. Infect. Dis., 10.1093/cid/ciaa410 Cifaldi, 2015, Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome, Arthritis Rheumatol., 67, 3037, 10.1002/art.39295 Clay, 2012, Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge, J. Virol., 86, 4234, 10.1128/JVI.06791-11 Clementi, 2020, Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro, bioRxiv Comar, 2019, Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection, MBio, 10, 1, 10.1128/mBio.00319-19 Corley, 2020, Comparative in vitro transcriptomic analyses of COVID-19 candidate therapy hydroxychloroquine suggest limited immunomodulatory evidence of SARS-CoV-2 host response genes, bioRxiv Dai, 2020, Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease, Science, 10.1126/science.abb4489 De Grove, 2016, Characterization and Quantification of Innate Lymphoid Cell Subsets in Human Lung, PLoS ONE, 11, e0145961, 10.1371/journal.pone.0145961 de Marcken, 2019, TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection, Sci. Signal., 12, eaaw1347, 10.1126/scisignal.aaw1347 de Wit, 2016, SARS and MERS: recent insights into emerging coronaviruses, Nat. Rev. Microbiol., 14, 523, 10.1038/nrmicro.2016.81 de Wit, 2020, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. USA, 117, 6771, 10.1073/pnas.1922083117 Del Valle, 2020, An inflammatory cytokine signature helps predict COVID-19 severity and death, medRxiv Deng, 2017, Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages, Proc. Natl. Acad. Sci. USA, 114, E4251, 10.1073/pnas.1618310114 Devaraj, 2007, Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus, J. Biol. Chem., 282, 32208, 10.1074/jbc.M704870200 Diao, 2020, Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19), Front. Immunol., 10.3389/fimmu.2020.00827 Díez, 2020, Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens, bioRxiv Dong, 2018, γδ T Cells Provide Protective Function in Highly Pathogenic Avian H5N1 Influenza A Virus Infection, Front. Immunol., 9, 2812, 10.3389/fimmu.2018.02812 Draghi, 2007, NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection, J. Immunol., 178, 2688, 10.4049/jimmunol.178.5.2688 Du, 2009, The spike protein of SARS-CoV--a target for vaccine and therapeutic development, Nat. Rev. Microbiol., 7, 226, 10.1038/nrmicro2090 Du, 2020, Multi-omics Evaluation of Gastrointestinal and Other Clinical Characteristics of SARS-CoV-2 and COVID-19, Gastroenterology, 10.1053/j.gastro.2020.03.045 Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, PNAS, 117, 9490, 10.1073/pnas.2004168117 Duev-Cohen, 2016, The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity, Oncotarget, 7, 13093, 10.18632/oncotarget.7597 Fang, 2020, Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19, J. Infect., 10.1016/j.jinf.2020.03.039 Fast, 2020, Potential T-cell and B-cell Epitopes of 2019-nCoV, bioRxiv Fauci, 2020, Covid-19 - Navigating the Uncharted, N. Engl. J. Med., 382, 1268, 10.1056/NEJMe2002387 Fei, 2020, Reduction of lymphocyte at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study, medRxiv Feng, 2020, Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics, medRxiv. Flores-Torres, 2019, Eosinophils and Respiratory Viruses, Viral Immunol., 32, 198, 10.1089/vim.2018.0150 Fogarty, 2020, COVID-19 Coagulopathy in Caucasian patients, Br. J. Haematol. Forni, 2015, The heptad repeat region is a major selection target in MERS-CoV and related coronaviruses, Sci. Rep., 5, 14480, 10.1038/srep14480 Frieman, 2007, Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane, J. Virol., 81, 9812, 10.1128/JVI.01012-07 Frieman, 2009, Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling, J. Virol., 83, 6689, 10.1128/JVI.02220-08 Fu, 2020, Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China, medRxiv Gangopadhyay, 2020, The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis, medRxiv Gao, 2020, Machine intelligence design of 2019-nCoV drugs, bioRxiv Gao, 2020, Prognostic value of NT-proBNP in patients with severe COVID-19, Respir Res., 21, 83, 10.1186/s12931-020-01352-w Gao, 2020, Rapid development of an inactivated vaccine for SARS-CoV-2, bioRxiv Gao, 2020, Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation, medRxiv Garulli, 2008, Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo, Clin. Vaccine Immunol., 15, 1497, 10.1128/CVI.00166-08 Gasteiger, 2015, Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs, Science, 350, 981, 10.1126/science.aac9593 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 105949, 10.1016/j.ijantimicag.2020.105949 Gautret, 2020, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med. Infect. Dis., 101663, 10.1016/j.tmaid.2020.101663 Giamarellos-Bourboulis, 2020, Complex Immune Dysregulation in COVID-19 Patients With Severe Respiratory Failure, Cell Host Microbe, 10.1016/j.chom.2020.04.009 Gioia, 2005, T-Cell response profiling to biological threat agents including the SARS coronavirus, Int. J. Immunopathol. Pharmacol., 18, 525, 10.1177/039463200501800312 Giron, 2020, On the Interactions of the Receptor-Binding Domain of SARS-CoV-1 and SARS-CoV-2 Spike Proteins with Monoclonal Antibodies and the Receptor ACE2, Virus Res., 285, 198021, 10.1016/j.virusres.2020.198021 Glasner, 2012, Elucidating the mechanisms of influenza virus recognition by Ncr1, PLoS ONE, 7, e36837, 10.1371/journal.pone.0036837 Gong, 2020, Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia, medRxiv Gordon, 2020, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, 10.1038/s41586-020-2286-9 Grein, 2020, Compassionate Use of Remdesivir for Patients with Severe Covid-19, N. Engl. J. Med., 10.1056/NEJMoa2007016 Grifoni, 2020, A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2, Cell Host Microbe, 27, 671, 10.1016/j.chom.2020.03.002 Guilliams, 2013, Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections, Mucosal Immunol., 6, 464, 10.1038/mi.2013.14 Guo, 2020, Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis, bioRxiv Hackbart, 2020, Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors, Proc. Nat. Acad. Sci. USA, 117, 8094, 10.1073/pnas.1921485117 Hadjadj, 2020, Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients, medRxiv Haveri, 2020, Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020, Euro Surveill., 25, 2000266, 10.2807/1560-7917.ES.2020.25.11.2000266 Hayden, 2019, Influenza virus polymerase inhibitors in clinical development, Curr. Opin. Infect. Dis., 32, 176, 10.1097/QCO.0000000000000532 He, 2005, Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets, Int. J. Infect. Dis., 9, 323, 10.1016/j.ijid.2004.07.014 Herold, 2020, Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19, J. Allergy Clin. Immunol., 10.1016/j.jaci.2020.05.008 Hirano, 2020, COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release System, Immunity, 52, 10.1016/j.immuni.2020.04.003 Ho, 2005, Neutralizing antibody response and SARS severity, Emerg. Infect. Dis., 11, 1730, 10.3201/eid1111.040659 Hsueh, 2004, Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus, Clin. Microbiol. Infect., 10, 1062, 10.1111/j.1469-0691.2004.01009.x Hu, 2017, The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination, J. Virol., 91, e02143, 10.1128/JVI.02143-16 Huang, 2011, SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage, PLoS Pathog., 7, e1002433, 10.1371/journal.ppat.1002433 Huang, 2011, Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus, PLoS Pathog., 7, e1001258, 10.1371/journal.ppat.1001258 Huang, 2019, High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study, Cell. Mol. Immunol., 16, 602, 10.1038/s41423-018-0164-2 Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease, medRxiv Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Huang, 2020, Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19, medRxiv Huang, 2020, Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China, medRxiv Hulme, 2020, A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19, medRxiv Hung, 2011, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin. Infect. Dis., 52, 447, 10.1093/cid/ciq106 Ivagnès, 2017, TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer, OncoImmunology, 7, e1386826, 10.1080/2162402X.2017.1386826 Ivanov, 2004, Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase, J. Virol., 78, 5619, 10.1128/JVI.78.11.5619-5632.2004 Ji, 2020, Analysis clinical features of COVID-19 infection in secondary epidemic area and report potential biomarkers in evaluation, medRxiv Jia, 2019, Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection, Emerg. Microbes Infect., 8, 760, 10.1080/22221751.2019.1620083 John, 2018, Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity, Vaccine, 36, 1689, 10.1016/j.vaccine.2018.01.029 Ju, 2020, Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature, 10.1038/s41586-020-2380-z Kamitani, 2009, A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein, Nat. Struct. Mol. Biol., 16, 1134, 10.1038/nsmb.1680 Kamphuis, 2006, Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia, Blood, 108, 3253, 10.1182/blood-2006-06-027599 Keyaerts, 2004, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun., 323, 264, 10.1016/j.bbrc.2004.08.085 Kim, 2019, Innate immune crosstalk in asthmatic airways: Innate lymphoid cells coordinate polarization of lung macrophages, J. Allergy Clin. Immunol., 143, 1769, 10.1016/j.jaci.2018.10.040 Kim, 2020, Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development, EBioMedicine, 102743, 10.1016/j.ebiom.2020.102743 Knoops, 2008, SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum, PLoS Biol., 6, e226, 10.1371/journal.pbio.0060226 Konig, 2020, Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome, medRxiv Kopecky-Bromberg, 2007, Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists, J. Virol., 81, 548, 10.1128/JVI.01782-06 Law, 2005, Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells, Blood, 106, 2366, 10.1182/blood-2004-10-4166 Ledford, 2020, Hopes rise for coronavirus drug remdesivir, Nature Lee, 2009, Tumor necrosis factor-alpha enhances IL-15-induced natural killer cell differentiation, Biochem. Biophys. Res. Commun., 386, 718, 10.1016/j.bbrc.2009.06.120 Lee, 2020, Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2, Clin Exp Pediatr, 63, 117, 10.3345/cep.2020.00290 Lei, 2020, Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig, Nat Commun., 11, 2070, 10.1038/s41467-020-16048-4 Lei, 2020, The phenotypic changes of γδ T cells in COVID-19 patients, medRxiv Levine, 2019, Monoclonal Antibody Therapy for Ebola Virus Disease, N. Engl. J. Med., 381, 2365, 10.1056/NEJMe1915350 Li, 2008, T cell responses to whole SARS coronavirus in humans, J. Immunol., 181, 5490, 10.4049/jimmunol.181.8.5490 Li, 2020, Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis, bioRxiv Li, 2020, Radiographic Findings and other Predictors in Adults with Covid-19, medRxiv Li, 2020, An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI), medRxiv Li, 2020, Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1, bioRxiv Liao, 2020, Single-cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19, Nat. Med., 10.1038/s41591-020-0901-9 Lin, 2007, Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine, Antivir. Ther. (Lond.), 12, 1107, 10.1177/135965350701200702 Lindesmith, 2003, Human susceptibility and resistance to Norwalk virus infection, Nat. Med., 9, 548, 10.1038/nm860 Liu, 2006, Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome, J. Infect. Dis., 193, 792, 10.1086/500469 Liu, 2019, Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection, JCI Insight, 4, e123158, 10.1172/jci.insight.123158 Liu, 2020, Persistent SARS-CoV-2 presence is companied with defects in adaptive immune system in non-severe COVID-19 patients, medRxiv Liu, 2020, Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, EBioMedicine, 55, 102763, 10.1016/j.ebiom.2020.102763 Liu, 2020, Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage, J. Transl. Med., 18, 206, 10.1186/s12967-020-02374-0 Liu, 2020, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov., 6, 16, 10.1038/s41421-020-0156-0 Liu, 2020, Prediction of the clinical outcome of COVID-19 patients using T lymphocyte subsets with 340 cases from Wuhan, China: a retrospective cohort study and a web visualization tool, medRxiv Liu, 2020, The role of interleukin-6 in monitoring severe case of coronavirus disease 2019, EMBO Mol. Med. Liu, 2020, Clinical features and outcomes of 2019 novel coronavirus-infected patients with cardiac injury, medRxiv Liu, 2020, Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study, Platelets, 1 Lo, 2015, AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy, Science, 349, 436, 10.1126/science.aaa1663 Lokugamage, 2015, Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin, J. Virol., 89, 10970, 10.1128/JVI.01352-15 Lokugamage, 2020, SARS-CoV-2 is sensitive to type I interferon pretreatment, bioRxiv Lon, 2020, Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2, bioRxiv Lou, 2020, Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset, medRxiv Lover, 2020, Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020), medRxiv Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 Lu, 2020, Adjuvant corticosteroid therapy for critically ill patients with COVID-19, medRxiv Luke, 2006, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann. Intern. Med., 145, 599, 10.7326/0003-4819-145-8-200610170-00139 Mantlo, 2020, Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection, Antiviral Res., 10.1016/j.antiviral.2020.104811 Mao, 2009, Influenza virus directly infects human natural killer cells and induces cell apoptosis, J. Virol., 83, 9215, 10.1128/JVI.00805-09 Marquardt, 2017, Human Lung Natural Killer Cells Are Predominantly Comprised of Highly Differentiated Hypofunctional CD69 − CD56 dim Cells, J. Allergy Clin. Immunol., 139, 1321, 10.1016/j.jaci.2016.07.043 Martin, 2008, A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial, Vaccine, 26, 6338, 10.1016/j.vaccine.2008.09.026 Medzhitov, 2012, Disease tolerance as a defense strategy, Science, 335, 936, 10.1126/science.1214935 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Menachery, 2017, MERS-CoV accessory orfs play key role for infection and pathogenesis, MBio, 8, 1, 10.1128/mBio.00665-17 Milewska, 2020, HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV, bioRxiv Minakshi, 2009, The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor, PLoS ONE, 4, e8342, 10.1371/journal.pone.0008342 Modjarrad, 2019, Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial, Lancet Infect. Dis., 19, 1013, 10.1016/S1473-3099(19)30266-X Molina, 2020, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med. Mal. Infect., 10.1016/j.medmal.2020.03.006 Monticelli, 2011, Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus, Nat. Immunol., 12, 1045, 10.1038/ni.2131 Moore, 2020, Cytokine release syndrome in severe COVID-19, Science, 368, 473, 10.1126/science.abb8925 Nailwal, 2019, Necroptosis in anti-viral inflammation, Cell Death Differ., 26, 4, 10.1038/s41418-018-0172-x Ng, 2016, Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection, Vaccine, 34, 2008, 10.1016/j.vaccine.2016.02.063 Ni, 2020, Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals, Immunity, 10.1016/j.immuni.2020.04.023 Nie, 2020, Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2, Emerg. Microbes Infect., 9, 680, 10.1080/22221751.2020.1743767 Nie, 2020, Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study, medRxiv Niemeyer, 2013, Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist, J. Virol., 87, 12489, 10.1128/JVI.01845-13 Nieto-Torres, 2015, Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome, Virology, 485, 330, 10.1016/j.virol.2015.08.010 Nikolich-Žugich, 2018, The twilight of immunity: emerging concepts in aging of the immune system, Nat. Immunol., 19, 10, 10.1038/s41590-017-0006-x Okabayashi, 2006, Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections, J. Med. Virol., 78, 417, 10.1002/jmv.20556 Okba, 2020, Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients, Emerg. Infect. Dis., 26, 10.3201/eid2607.200841 Ong, 2020, A dynamic immune response shapes COVID-19 progression, Cell Host Microbe, 10.1016/j.chom.2020.03.021 Page, 2012, Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection, J. Virol., 86, 13334, 10.1128/JVI.01689-12 Pan, 2020, Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro, bioRxiv Pardi, 2017, Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination, Nature, 543, 248, 10.1038/nature21428 Park, 2020, Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2, bioRxiv Payne, 2016, Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus, Emerg. Infect. Dis., 22, 1824, 10.3201/eid2210.160706 Pei, 2020, Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences, medRxiv Perlman, 2005, Immunopathogenesis of coronavirus infections: implications for SARS, Nat. Rev. Immunol., 5, 917, 10.1038/nri1732 Pfaender, 2020, LY6E impairs coronavirus fusion and confers immune control of viral disease, bioRxiv Pinto, 2020, Structural and functional analysis of a potent sarbecovirus neutralizing antibody, bioRxiv Poor, 2020, COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis, medRxiv Prokunina-Olsson, 2020, COVID-19 and emerging viral infections: The case for interferon lambda, J. Exp. Med., 217, e20200653, 10.1084/jem.20200653 Qin, 2020, Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China, Clin. Infect. Dis. Qiu, 2005, Antibody responses to individual proteins of SARS coronavirus and their neutralization activities, Microbes Infect., 7, 882, 10.1016/j.micinf.2005.02.006 Qu, 2020, Platelet-to-lymphocyte Ratio Is Associated With Prognosis in Patients With Coronavirus disease-19, J. Med. Virol., 10.1002/jmv.25767 Quinlan, 2020, The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement, bioRxiv Rabouw, 2016, Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses, PLoS Pathog., 12, e1005982, 10.1371/journal.ppat.1005982 Ramsuran, 2018, Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells, Science, 359, 86, 10.1126/science.aam8825 Reed, 1984, The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains, J. Med. Virol., 13, 179, 10.1002/jmv.1890130208 Renieri, 2020, ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population, medRxiv Roumier, 2020, Interleukin-6 blockade for severe COVID-19, medRxiv Sanders, 2020, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA, 10.1001/jama.2020.6019 Savarino, 2003, Effects of chloroquine on viral infections: an old drug against today’s diseases?, Lancet Infect. Dis., 3, 722, 10.1016/S1473-3099(03)00806-5 Schrezenmeier, 2020, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat. Rev. Rheumatol., 16, 155, 10.1038/s41584-020-0372-x Shamshirian, 2020, Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis, medRxiv Shang, 2020, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet, 395, 683, 10.1016/S0140-6736(20)30361-5 Shao, 2020, Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study, medRxiv Sheahan, 2017, ). Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses, Sci. Transl. Med., 9, eaal3653, 10.1126/scitranslmed.aal3653 Sheahan, 2020, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun., 11, 222, 10.1038/s41467-019-13940-6 Shen, 2020, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783 Shi, 2014, SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome, J. Immunol., 193, 3080, 10.4049/jimmunol.1303196 Shi, 2019, SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes, Cell Death Discov., 5, 101, 10.1038/s41420-019-0181-7 Shi, 2020, Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China, JAMA Cardiol., 10.1001/jamacardio.2020.0950 Shiow, 2006, CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs, Nature, 440, 540, 10.1038/nature04606 Siu, 2009, Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex, J. Biol. Chem., 284, 16202, 10.1074/jbc.M109.008227 Siu, 2014, Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response, J. Virol., 88, 4866, 10.1128/JVI.03649-13 Siu, 2019, Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC, FASEB J., 33, 8865, 10.1096/fj.201802418R Sivori, 2019, Human NK cells: surface receptors, inhibitory checkpoints, and translational applications, Cell. Mol. Immunol., 16, 430, 10.1038/s41423-019-0206-4 Song, 2019, From SARS to MERS, Thrusting Coronaviruses into the Spotlight, Viruses, 11, 59, 10.3390/v11010059 Song, 2020, COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients, medRxiv Stanifer, 2020, Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells, bioRxiv Stawiski, 2020, Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility, bioRxiv Sui, 2004, Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. USA, 101, 2536, 10.1073/pnas.0307140101 Sui, 2005, Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants, J. Virol., 79, 5900, 10.1128/JVI.79.10.5900-5906.2005 Sun, 2012, Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling, PLoS ONE, 7, e30802, 10.1371/journal.pone.0030802 Sun, 2020, SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development, bioRxiv Tai, 2020, Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell. Mol. Immunol., 10.1038/s41423-020-0400-4 Tan, 2020, Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Signal Transduct. Target. Ther., 5, 33, 10.1038/s41392-020-0148-4 Tan, 2020, Viral Kinetics and Antibody Responses in Patients with COVID-19, medRxiv Tanaka, 2016, Immunotherapeutic implications of IL-6 blockade for cytokine storm, Immunotherapy, 8, 959, 10.2217/imt-2016-0020 Tang, 2011, Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study, J. Immunol., 186, 7264, 10.4049/jimmunol.0903490 Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemost., 18, 844, 10.1111/jth.14768 Tang, 2020, Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, medRxiv Tanne, 2020, Covid-19: FDA approves use of convalescent plasma to treat critically ill patients, BMJ, 368, m1256, 10.1136/bmj.m1256 Taylor, 2015, Fc receptors in antibody-dependent enhancement of viral infections, Immunol. Rev., 268, 340, 10.1111/imr.12367 ter Meulen, 2004, Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets, Lancet, 363, 2139, 10.1016/S0140-6736(04)16506-9 Terpos, 2020, Hematological findings and complications of COVID-19, Am. J. Hematol., 10.1002/ajh.25829 Tetro, 2020, Is COVID-19 receiving ADE from other coronaviruses?, Microbes Infect., 22, 72, 10.1016/j.micinf.2020.02.006 Thanh Le, 2020, The COVID-19 vaccine development landscape, Nat. Rev. Drug Discov., 19, 305, 10.1038/d41573-020-00073-5 Thevarajan, 2020, Breadth of Concomitant Immune Responses Prior to Patient Recovery: A Case Report of Non-Severe COVID-19, Nat. Med., 26, 453, 10.1038/s41591-020-0819-2 Thomé, 2013, Chloroquine: modes of action of an undervalued drug, Immunol. Lett., 153, 50, 10.1016/j.imlet.2013.07.004 Thomé, 2013, Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis, PLoS ONE, 8, e65913, 10.1371/journal.pone.0065913 Thornbrough, 2016, Middle east respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation, MBio, 7, e00258, 10.1128/mBio.00258-16 Tian, 2020, Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies, Mod. Pathol., 10.1038/s41379-020-0536-x Tian, 2020, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg. Microbes Infect., 9, 382, 10.1080/22221751.2020.1729069 To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect. Dis., 20, 565, 10.1016/S1473-3099(20)30196-1 Traggiai, 2004, An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus, Nat. Med., 10, 871, 10.1038/nm1080 Travaglini, 2020, A molecular cell atlas of the human lung from single cell RNA sequencing, bioRxiv Trimble, 2015, Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial, Lancet, 386, 2078, 10.1016/S0140-6736(15)00239-1 Vabret, 2020, Advancing scientific knowledge in times of pandemics, Nat. Rev. Immunol., 10.1038/s41577-020-0319-0 Varga, 2020, Endothelial Cell Infection and Endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5 Vincent, 2005, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J., 2, 69, 10.1186/1743-422X-2-69 Vivier, 2018, Innate Lymphoid Cells: 10 Years On, Cell, 174, 1054, 10.1016/j.cell.2018.07.017 Von Holle, 2019, Influenza and Antibody-Dependent Cellular Cytotoxicity, Front. Immunol., 10, 1457, 10.3389/fimmu.2019.01457 Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 Walter, 2018, Multidimensional assessment of alveolar T cells in critically ill patients, JCI Insight, 3, e123287, 10.1172/jci.insight.123287 Wan, 2020, Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), medRxiv Wan, 2020, Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus, J. Virol., 94, e00127-20, 10.1128/JVI.00127-20 Wan, 2020, Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry, J. Virol., 94, e02015, 10.1128/JVI.02015-19 Wang, 2020, C-reactive Protein Levels in the Early Stage of COVID-19, Med. Mal. Infect., 10.1016/j.medmal.2020.03.007 Wang, 2005, Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS, Respir. Res., 6, 42, 10.1186/1465-9921-6-42 Wang, 2011, Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection, Viral Immunol., 24, 421, 10.1089/vim.2011.0024 Wang, 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun. Wang, 2020 Wang, 2020, No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019: A Retrospective Cohort Study, medRxiv Wang, 2020, Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia, J. Infect. Dis., 221, 1762, 10.1093/infdis/jiaa150 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res., 30, 269, 10.1038/s41422-020-0282-0 Wang, 2020, The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis, medRxiv Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 10.1016/S0140-6736(20)31022-9 Wang, 2020, Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China, medRxiv Wathelet, 2007, Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain, J. Virol., 81, 11620, 10.1128/JVI.00702-07 Weiskopf, 2020, Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome, medRxiv Wen, 2020, Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing, Cell Discov. Wilk, 2020, A single-cell atlas of the peripheral immune response to severe COVID-19, medRxiv Williamson, 2020, Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, bioRxiv Wölfel, 2020, Virological assessment of hospitalized patients with COVID-2019, Nature, 10.1038/s41586-020-2196-x Wong, 2004, Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome, Clin. Exp. Immunol., 136, 95, 10.1111/j.1365-2249.2004.02415.x 2020 2020 Wrapp, 2020, Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies, Cell, 181, 10.1016/j.cell.2020.04.031 Wu, 2020, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern. Med., 10.1001/jamainternmed.2020.0994 Wu, 2020, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, medRxiv Wu, 2020, Identification of Human Single-Domain Antibodies against SARS-CoV-2, Cell Host Microbe, 10.1016/j.chom.2020.04.023 Wynants, 2020, Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal, BMJ, 369, m1328, 10.1136/bmj.m1328 Xia, 2004, The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome, Am. J. Clin. Pathol., 121, 507, 10.1309/WPK7Y2XKNF4CBF3R Xiang, 2020, Potential biochemical markers to identify severe cases among COVID-19 patients, medRxiv Xiang, 2020, Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19), medRxiv Xiong, 2020, Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2, bioRxiv Xu, 2020, Acute Myocardial Injury of Patients with Coronavirus Disease 2019, medRxiv Xu, 2020, Effective treatment of severe COVID-19 patients with tocilizumab, Proc. Natl. Acad. Sci. USA, 10.1073/pnas.2005615117 Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med., 8, 420, 10.1016/S2213-2600(20)30076-X Yamamoto, 2020, Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro, bioRxiv Yan, 2020, Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection, Eur. Respir. J., 10.1183/13993003.00799-2020 Yan, 2020, Prediction of criticality in patients with severe Covid-19 infection using three clinical features: a machine learning-based prognostic model with clinical data in Wuhan, medRxiv Yang, 2015, Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets, Sci. Rep., 5, 17554, 10.1038/srep17554 Yang, 2020, Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2, medRxiv Yang, 2020, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J. Allergy Clin. Immunol., 10.1016/j.jaci.2020.04.027 Yang, 2020, The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis, J. Infect., 10.1016/j.jinf.2020.03.062 Yao, 2020, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 10.1093/cid/ciaa237 Yao, 2020, [A pathological report of three COVID-19 cases by minimally invasive autopsies], Zhonghua Bing Li Xue Za Zhi, 49, E009 Ying, 2015, Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections, Microbes Infect., 17, 142, 10.1016/j.micinf.2014.11.008 Yip, 2014, Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus, Virol. J., 11, 82, 10.1186/1743-422X-11-82 Yu, 2020, ). Immunodepletion with Hypoxemia: A Potential High Risk Subtype of Coronavirus Disease 2019, medRxiv Yuan, 2020, A Highly Conserved Cryptic Epitope in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV, Science, 868, 630, 10.1126/science.abb7269 Yudanin, 2019, Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity, Immunity, 50, 505, 10.1016/j.immuni.2019.01.012 Zeng, 2020, Mortality of COVID-19 is Associated with Cellular Immune Function Compared to Immune Function in Chinese Han Population, medRxiv Zha, 2020, Corticosteroid Treatment of Patients with Coronavirus Disease 2019 (COVID-19), Med. J. Aust., 10.5694/mja2.50577 Zhang, 2006, Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals, J. Med. Virol., 78, 1, 10.1002/jmv.20499 Zhang, 2020, Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19, medRxiv Zhang, 2020, Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection, Chest, 10.1016/j.chest.2020.03.039 Zhang, 2020, COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome, medRxiv Zhang, 2020, Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing, medRxiv Zhao, 2009, Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice, PLoS Pathog., 5, e1000636, 10.1371/journal.ppat.1000636 Zhao, 2011, The immune responses of HLA-A∗0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848, Vaccine, 29, 6670, 10.1016/j.vaccine.2011.06.100 Zhao, 2014, Interferon induction of IFITM proteins promotes infection by human coronavirus OC43, Proc. Natl. Acad. Sci. USA, 111, 6756, 10.1073/pnas.1320856111 Zhao, 2018, Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses, J. Virol., 92, e01535-17, 10.1128/JVI.01535-17 Zhao, 2020, Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019, Clin. Infect. Dis., 10.1093/cid/ciaa344 Zhao, 2020, Relationship between the ABO Blood Group and the COVID-19 Susceptibility, medRxiv Zhao, 2020, LY6E Restricts the Entry of Human Coronaviruses, including the currently pandemic SARS-CoV-2, bioRxiv Zhao, 2020, Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis, medRxiv Zheng, 2020, Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV, Cell. Mol. Immunol., 17, 536, 10.1038/s41423-020-0385-z Zheng, 2013, γδ-T cells: an unpolished sword in human anti-infection immunity, Cell. Mol. Immunol., 10, 50, 10.1038/cmi.2012.43 Zheng, 2020, Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients, Cell. Mol. Immunol., 17, 541, 10.1038/s41423-020-0401-3 Zheng, 2020, Functional exhaustion of antiviral lymphocytes in COVID-19 patients, Cell. Mol. Immunol., 17, 533, 10.1038/s41423-020-0402-2 Zhou, 2014, Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis, J. Infect. Dis., 209, 1331, 10.1093/infdis/jit504 Zhou, 2018, Prospects for a MERS-CoV spike vaccine, Expert Rev. Vaccines, 17, 677, 10.1080/14760584.2018.1506702 Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Zhou, 2020, Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus, bioRxiv Zhou, 2020, Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Natl. Sci. Rev. Zhou, 2020, A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China, medRxiv Zhu, 2007, Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 104, 12123, 10.1073/pnas.0701000104 Zhu, 2015, Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial, Lancet, 385, 2272, 10.1016/S0140-6736(15)60553-0 Zhu, 2017, Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 389, 621, 10.1016/S0140-6736(16)32617-4 Ziegler, 2020, SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues, Cell, 10.1016/j.cell.2020.04.035 Zietz, 2020, Testing the association between blood type and COVID-19 infection, intubation, and death, medRxiv